PBLS (Parabilis Medicines) Interest Coverage: 0 (At Loss) (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBLS Parabilis Medicines Inc PBLS
10 GF Score
Price $31.50
! 1 Warning Sign
View Full Analysis

What is Parabilis Medicines Interest Coverage?

Parabilis Medicines PBLS -4.66% 10 Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus rates PBLS with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 376 Biotechnology companies, Parabilis Medicines ranks worse than 265957.18% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Parabilis Medicines's Operating Income for the six months ended in Dec. 2025 was $-152.08 Mil. Parabilis Medicines's Interest Expense for the six months ended in Dec. 2025 was $-1.52 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Parabilis Medicines's Interest Coverage or its related term are showing as below:


PBLS's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.135
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Parabilis Medicines  (NAS:PBLS) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Parabilis Medicines Interest Coverage Related Terms


Parabilis Medicines Interest Coverage Historical Data

* Premium members only.

The historical data trend for Parabilis Medicines's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Parabilis Medicines Interest Coverage Chart

Parabilis Medicines Annual Data
Trend Dec24 Dec25
Interest Coverage
0.00 0.00

Parabilis Medicines Semi-Annual Data
Dec24 Dec25
Interest Coverage 0.00 0.00

PBLS vs IDYA, ELVN, BEAM: Interest Coverage Comparison

For the Biotechnology subindustry, Parabilis Medicines's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parabilis Medicines Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Parabilis Medicines's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Parabilis Medicines's Interest Coverage falls into.


PBLS
10GF Score
Parabilis Medicines Inc PBLS
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parabilis Medicines Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Parabilis Medicines's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Parabilis Medicines's Interest Expense was $-1.52 Mil. Its Operating Income was $-152.08 Mil. And its Long-Term Debt & Capital Lease Obligation was $37.81 Mil.

Parabilis Medicines did not have earnings to cover the interest expense.

Parabilis Medicines's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Here, for the six months ended in Dec. 2025, Parabilis Medicines's Interest Expense was $-1.52 Mil. Its Operating Income was $-152.08 Mil. And its Long-Term Debt & Capital Lease Obligation was $37.81 Mil.

Parabilis Medicines did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of 0 (At Loss) mean?
Parabilis Medicines (PBLS) has a Interest Coverage of 0 (At Loss) as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Parabilis Medicines and its competitors. According to the industry distribution chart, Parabilis Medicines ranks #999999 out of 376 companies in the Biotechnology industry.
Is Parabilis Medicines' Interest Coverage too high?
Parabilis Medicines' current Interest Coverage is 0 (At Loss). Based on the distribution chart, Parabilis Medicines ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' Interest Coverage compare to IDYA and ELVN?
According to the Biotechnology industry distribution chart, Parabilis Medicines ranks #999999 out of 376 companies for Interest Coverage. This places Parabilis Medicines in the lower half of its industry. The industry median Interest Coverage is 106.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.14, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Parabilis Medicines and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parabilis Medicines's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). Parabilis Medicines' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parabilis Medicines Business Description

Address 30 Acorn Park Drive, Cambridge Discovery Park, Cambridge, MA, USA, 02140
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score

Get the complete analysis for PBLS

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.50
Price